Company Description
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally.
It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally.
The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States.
The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products.
The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018.
Bausch Health Companies Inc. is headquartered in Laval, Canada.
| Country | Canada |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 20,270 |
| CEO | Thomas J. Appio |
Contact Details
Address: 2150 St. Elzear Blvd. West, Laval Quebec, A8 H7L 4A8 Quebec, Canada | |
| Phone | 514-744-6792 |
| Website | bauschhealth.com |
Stock Details
| Ticker Symbol | BHC |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000885590 |
| CUSIP Number | 071734107 |
| ISIN Number | CA0717341071 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thomas J. Appio | Chief Executive Officer and Director |
| John S. Barresi | Senior Vice President, Controller, Chief Accounting Officer and Interim Chief Financial Officer |
| Seana Carson | Executive Vice President and General Counsel |
| Mirza Dautbegovic | Senior Vice President and Chief Operating Officer |
| Josh Coyle | Senior Vice President of Sales and Salix |
| Kathleen Fitzpatrick | Senior Vice President and Chief Human Resources Officer |
| Dr. Tage Ramakrishna M.D. | Chief Medical Officer and President of Research & Development |
| Jeff Hartness | Executive Vice President of Market Access, Commercial Operations, Neurology, Generics and Government Affairs |
| Dr. Graham Jackson | Senior Vice President and Chief Quality Officer |
| Cees Heiman | Senior Vice President of Europe and Canada |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 4, 2024 | ARS | Filing |
| Apr 4, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 4, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 4, 2024 | 144 | Filing |
| Feb 22, 2024 | 10-K | Annual Report |
| Feb 22, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 7, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 1, 2024 | 8-K | Current Report |
| Dec 5, 2023 | 144 | Filing |